RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental donor CAR-T therapy tested in lymphoma – trial halted early
Disease control TerminatedThis early-phase trial tested a new therapy called ATA3219, which uses immune cells from a healthy donor to attack cancer cells in people with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aimed to check safety and see if the treatment works, but it was stopped ea…
Matched conditions: RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Atara Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental CAR t combo trial halted early – only 2 patients enrolled
Disease control TerminatedThis study tested whether adding an extra drug (ALLO-647) to standard chemotherapy before a special immune cell treatment (CAR T) could help adults with a hard-to-treat type of lymphoma. Only 2 people joined before the trial was stopped early. The goal was to see if the new combi…
Matched conditions: RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC